

Edgar Schmitt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5431402/publications.pdf>

Version: 2024-02-01

55
papers

8,568
citations

94433

37
h-index

114465

63
g-index

67
all docs

67
docs citations

67
times ranked

8280
citing authors

#	ARTICLE	IF	CITATIONS
1	In Activated Murine Mast Cells, NFATc2 Is Critical for the Production of Autocrine IL-3, Thereby Promoting the Expression of IL-9. <i>Journal of Immunology</i> , 2021, 206, 67-76.	0.8	4
2	The Development of Vaccines from Synthetic Tumor-Associated Mucin Glycopeptides and their Glycosylation-Dependent Immune Response. <i>Chemical Record</i> , 2021, 21, 3313-3331.	5.8	13
3	Evaluation of a novel monoclonal antibody against tumor-associated MUC1 for diagnosis and prognosis of breast cancer. <i>International Journal of Medical Sciences</i> , 2019, 16, 1188-1198.	2.5	19
4	Reduced Breast Tumor Growth after Immunization with a Tumor-Restricted MUC1 Glycopeptide Conjugated to Tetanus Toxoid. <i>Cancer Immunology Research</i> , 2019, 7, 113-122.	3.4	29
5	Mannose-Decorated Multicomponent Supramolecular Polymers Trigger Effective Uptake into Antigen-Presenting Cells. <i>ChemBioChem</i> , 2018, 19, 912-916.	2.6	33
6	Synthetic MUC1 Antitumor Vaccine with Incorporated 2,3-Sialyl- Carbohydrate Antigen Inducing Strong Immune Responses with Isotype Specificity. <i>ChemBioChem</i> , 2018, 19, 1142-1146.	2.6	13
7	A Synthetic MUC1 Anticancer Vaccine Containing Mannose Ligands for Targeting Macrophages and Dendritic Cells. <i>ChemMedChem</i> , 2018, 13, 25-29.	3.2	45
8	Tumor immunoevasion via acidosis-dependent induction of regulatory tumor-associated macrophages. <i>Nature Immunology</i> , 2018, 19, 1319-1329.	14.5	274
9	Immunogenicity of a Fully Synthetic MUC1 Glycopeptide Antitumor Vaccine Enhanced by Poly(I:C) as a TLR3-Activating Adjuvant. <i>ChemMedChem</i> , 2017, 12, 722-727.	3.2	21
10	Discovery and initial characterization of Th9 cells: the early years. <i>Seminars in Immunopathology</i> , 2017, 39, 5-10.	6.1	20
11	Microarray Analysis of Antibodies Induced with Synthetic Antitumor Vaccines: Specificity against Diverse Mucin Core Structures. <i>Chemistry - A European Journal</i> , 2017, 23, 3875-3884.	3.3	28
12	Immunization with a Synthetic Human MUC1 Glycopeptide Vaccine against Tumor-Associated MUC1 Breaks Tolerance in Human MUC1 Transgenic Mice. <i>ChemMedChem</i> , 2017, 12, 1424-1428.	3.2	24
13	Combined B, T and NK Cell Deficiency Accelerates Atherosclerosis in BALB/c Mice. <i>PLoS ONE</i> , 2016, 11, e0157311.	2.5	4
14	Ein durch eine synthetische Glycopeptid-Vakzine induzierter monoklonaler Antikörper unterscheidet normale von malignen Brustzellen und ermöglicht die Diagnose von humanen Pankreaskarzinomen. <i>Angewandte Chemie</i> , 2016, 128, 2944-2949.	2.0	12
15	A Synthetic Glycopeptide Vaccine for the Induction of a Monoclonal Antibody that Differentiates between Normal and Tumor Mammary Cells and Enables the Diagnosis of Human Pancreatic Cancer. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 2894-2898.	13.8	53
16	Glycopeptide-functionalized gold nanoparticles for antibody induction against the tumor associated mucin-1 glycoprotein. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 1132-1135.	3.0	46
17	Synthesis and biological evaluation of a novel MUC1 glycopeptide conjugate vaccine candidate comprising a 4'-deoxy-4'-fluoro-Thomsen-Friedenreich epitope. <i>Beilstein Journal of Organic Chemistry</i> , 2015, 11, 155-161.	2.2	38
18	CpG-Loaded Multifunctional Cationic Nanohydrogel Particles as Self-Adjuvanting Glycopeptide Antitumor Vaccines. <i>Advanced Healthcare Materials</i> , 2015, 4, 522-527.	7.6	46

#	ARTICLE	IF	CITATIONS
19	Antibody Induction Directed against the Tumor-Associated MUC4 Glycoprotein. ChemBioChem, 2015, 16, 959-967.	2.6	21
20	Tick Salivary Sialostatin L Represses the Initiation of Immune Responses by Targeting IRF4-Dependent Transcription in Murine Mast Cells. Journal of Immunology, 2015, 195, 621-631.	0.8	35
21	The role of recent thymic emigrant-regulatory T-cell (RTE-Treg) differentiation during pregnancy. Immunology and Cell Biology, 2015, 93, 858-867.	2.3	32
22	A Fully Synthetic Four-Component Antitumor Vaccine Consisting of a Mucin Glycopeptide Antigen Combined with Three Different T-Helper-Cell Epitopes. Angewandte Chemie - International Edition, 2014, 53, 14245-14249.	13.8	57
23	A Fully Synthetic Glycopeptide Antitumor Vaccine Based on Multiple Antigen Presentation on a Hyperbranched Polymer. Chemistry - A European Journal, 2014, 20, 4232-4236.	3.3	41
24	Nitric oxide enhances Th9 cell differentiation and airway inflammation. Nature Communications, 2014, 5, 4575.	12.8	59
25	Water-Soluble Polymers Coupled with Glycopeptide Antigens and T-Cell Epitopes as Potential Antitumor Vaccines. Angewandte Chemie - International Edition, 2013, 52, 10652-10656.	13.8	83
26	The Tick Salivary Protein Sialostatin L Inhibits the Th9-Derived Production of the Asthma-Promoting Cytokine IL-9 and Is Effective in the Prevention of Experimental Asthma. Journal of Immunology, 2012, 188, 2669-2676.	0.8	68
27	From interleukin-9 to T helper 9 cells. Annals of the New York Academy of Sciences, 2012, 1247, 56-68.	3.8	91
28	Amazing IL-9: revealing a new function for an "old" cytokine. Journal of Clinical Investigation, 2012, 122, 3857-3859.	8.2	23
29	Synthetic Antitumor Vaccines Containing MUC1 Glycopeptides with Two Immunodominant Domains-Induction of a Strong Immune Response against Breast Tumor Tissues. Angewandte Chemie - International Edition, 2011, 50, 9977-9981.	13.8	90
30	Fully Synthetic Vaccines Consisting of Tumor-Associated MUC1 Glycopeptides and a Lipopeptide Ligand of the Toll-Like Receptor-2. Angewandte Chemie - International Edition, 2010, 49, 3688-3692.	13.8	114
31	Synthetic Antitumor Vaccines from Tetanus Toxoid Conjugates of MUC1 Glycopeptides with the Thomsen-Friedenreich Antigen and a Fluorine-Substituted Analogue. Angewandte Chemie - International Edition, 2010, 49, 8498-8503.	13.8	136
32	Interferon-Regulatory Factor 4 Is Essential for the Developmental Program of T Helper 9 Cells. Immunity, 2010, 33, 192-202.	14.3	465
33	A Synthetic Vaccine Consisting of a Tumor-Associated Sialyl-T _N -MUC1 Tandem-Repeat Glycopeptide and Tetanus Toxoid: Induction of a Strong and Highly Selective Immune Response. Angewandte Chemie - International Edition, 2009, 48, 7551-7555.	13.8	135
34	Tumor-Associated MUC1 Tandem-Repeat Glycopeptide Microarrays to Evaluate Serum- and Monoclonal-Antibody Specificity. Angewandte Chemie - International Edition, 2009, 48, 8263-8267.	13.8	58
35	Synthetic Vaccines Consisting of Tumor-Associated MUC1 Glycopeptide Antigens and a T-Cell Epitope for the Induction of a Highly Specific Humoral Immune Response. Angewandte Chemie - International Edition, 2008, 47, 7551-7556.	13.8	105
36	p38 MAP kinase drives the expression of mast cell-derived IL-9 via activation of the transcription factor GATA-1. Molecular Immunology, 2007, 44, 926-933.	2.2	33

#	ARTICLE	IF	CITATIONS
37	Activation of Mast Cells by Streptolysin O and Lipopolysaccharide. , 2006, 315, 393-404.		18
38	Specific and Redundant Roles for NFAT Transcription Factors in the Expression of Mast Cell-Derived Cytokines. Journal of Immunology, 2006, 177, 6667-6674.	0.8	92
39	A Fully Synthetic Vaccine Consisting of a Tumor-Associated Glycopeptide Antigen and a T-Cell Epitope for the Induction of a Highly Specific Humoral Immune Response. Angewandte Chemie - International Edition, 2005, 44, 7630-7635.	13.8	130
40	Treatment of Allergic Airway Inflammation and Hyperresponsiveness by Antisense-Induced Local Blockade of Gata-3 Expression. Journal of Experimental Medicine, 2001, 193, 1247-1260.	8.5	238
41	Identification and Functional Characterization of Human Cd4+Cd25+ T Cells with Regulatory Properties Isolated from Peripheral Blood. Journal of Experimental Medicine, 2001, 193, 1285-1294.	8.5	1,114
42	IL-9 and IL-13 Production by Activated Mast Cells Is Strongly Enhanced in the Presence of Lipopolysaccharide: NF- κ B Is Decisively Involved in the Expression of IL-9. Journal of Immunology, 2001, 166, 4391-4398.	0.8	137
43	H2-M, a facilitator of MHC class II peptide loading, and its negative modulator H2-O are differentially expressed in response to proinflammatory cytokines. Immunogenetics, 2000, 51, 794-804.	2.4	15
44	Murine Bone Marrow-Derived Mast Cells as Potent Producers of IL-9: Costimulatory Function of IL-10 and α Kit Ligand in the Presence of IL-1. Journal of Immunology, 2000, 164, 5549-5555.	0.8	106
45	In Activated Mast Cells, IL-1 Up-Regulates the Production of Several Th2-Related Cytokines Including IL-9. Journal of Immunology, 2000, 164, 5556-5563.	0.8	133
46	Induction of Interleukin 10-Producing, Nonproliferating Cd4+ T Cells with Regulatory Properties by Repetitive Stimulation with Allogeneic Immature Human Dendritic Cells. Journal of Experimental Medicine, 2000, 192, 1213-1222.	8.5	1,425
47	Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development. European Journal of Immunology, 1998, 28, 3231-3239.	2.9	274
48	Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development. , 1998, 28, 3231.		1
49	Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development. European Journal of Immunology, 1998, 28, 3231-3239.	2.9	3
50	Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. European Journal of Immunology, 1997, 27, 3135-3142.	2.9	1,087
51	Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. European Journal of Immunology, 1996, 26, 934-938.	2.9	350
52	Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses <i>in vivo</i> . European Journal of Immunology, 1995, 25, 823-829.	2.9	331
53	Mast cell growth-enhancing activity (MEA) is structurally related and functionally identical to the novel mouse T cell growth factor P40/TCGFIII (interleukin 9). European Journal of Immunology, 1990, 20, 1413-1416.	2.9	282
54	Establishment of different T cell sublines using either interleukin 2 or interleukin 4 as growth factors. European Journal of Immunology, 1990, 20, 1709-1715.	2.9	52

#	ARTICLE	IF	CITATIONS
55	Tcgfiii/p40 is produced by naive murine cd4+ t cells but is not a general t cell growth factor*. European Journal of Immunology, 1989, 19, 2167-2170.	2.9	110